LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances) · 9.4M shares · -53%/yr ↓ buyback · EDGAR filings ↗
Reference price $5.37 · est. market cap ~$50M — last insider sale, 2026-03-04 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D40Clinical/early-stage biotech — clinical-stage biopharma micro-cap, modestly funded.
Strengths
- Liquidity — current ratio 1.9 (26th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Buying back stockNet buyback — share count -53%/yr over 3y
- Notable holderHeld by 2 notable fund(s): RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP (as of 2026-03-31)
- Insider sellingInsider selling — 10 open-market sale(s) by 5 insider(s) (cluster of 5 insiders, last 6mo) Form 4 ↗
Key metrics
Return on equity
-380.0%
Return on assets
-114.6%
Current ratio
1.9×
Tangible book value
$28M
Cash & investments
$88M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-04 | Litton Mark James | Sell | 5.2K | $5.37 |
| 2026-03-04 | Renninger Robert | Sell | 906 | $5.37 |
| 2026-03-04 | Worthington Mark | Sell | 1.3K | $5.37 |
| 2026-03-04 | CHURCH KEVIN | Sell | 1.4K | $5.37 |
| 2026-03-04 | San Martin Javier | Sell | 1.7K | $5.37 |
| 2026-03-03 | Litton Mark James | Option exercise | 22K | — |
| 2026-03-03 | San Martin Javier | Option exercise | 7.4K | — |
| 2026-03-03 | Worthington Mark | Option exercise | 5.7K | — |
| 2026-03-03 | Renninger Robert | Option exercise | 3.9K | — |
| 2026-03-03 | CHURCH KEVIN | Option exercise | 5.9K | — |
| 2026-01-02 | San Martin Javier | Sell | 1.6K | $6.88 |
| 2026-01-02 | Renninger Robert | Sell | 297 | $6.88 |
| 2026-01-02 | Worthington Mark | Sell | 876 | $6.88 |
| 2026-01-02 | Litton Mark James | Sell | 2.6K | $6.88 |
| 2026-01-02 | CHURCH KEVIN | Sell | 876 | $6.88 |
| 2025-12-31 | San Martin Javier | Option exercise | 4.7K | — |
| 2025-12-31 | Renninger Robert | Option exercise | 1.2K | — |
| 2025-12-31 | CHURCH KEVIN | Option exercise | 3.7K | — |
| 2025-12-31 | Worthington Mark | Option exercise | 3.7K | — |
| 2025-12-31 | Litton Mark James | Option exercise | 11K | — |
| 2025-12-23 | PERCEPTIVE ADVISORS LLC | Grant | 330K | $6.35 |
| 2025-12-23 | PERCEPTIVE ADVISORS LLC | Grant | 989K | $6.35 |
| 2025-11-18 | CHURCH KEVIN | Grant | 1.0K | $2.31 |
| 2025-11-18 | Renninger Robert | Grant | 1.0K | $2.31 |
| 2025-07-01 | CHURCH KEVIN | Sell | 8.5K | $0.29 |
| 2025-07-01 | Renninger Robert | Sell | 2.9K | $0.29 |
| 2025-07-01 | Litton Mark James | Sell | 25K | $0.29 |
| 2025-07-01 | Worthington Mark | Sell | 8.5K | $0.29 |
| 2025-07-01 | San Martin Javier | Sell | 11K | $0.29 |
| 2025-06-30 | Renninger Robert | Option exercise | 12K | — |
| 2025-06-30 | CHURCH KEVIN | Option exercise | 37K | — |
| 2025-06-30 | Litton Mark James | Option exercise | 108K | — |
| 2025-06-30 | San Martin Javier | Option exercise | 47K | — |
| 2025-06-30 | Worthington Mark | Option exercise | 37K | — |
| 2025-05-19 | CHURCH KEVIN | Grant | 10K | $0.23 |
| 2025-05-19 | Renninger Robert | Grant | 10K | $0.23 |
| 2025-01-02 | Worthington Mark | Sell | 8.5K | $0.56 |
| 2025-01-02 | San Martin Javier | Sell | 11K | $0.56 |
| 2025-01-02 | Litton Mark James | Sell | 25K | $0.56 |
| 2025-01-02 | CHURCH KEVIN | Sell | 8.5K | $0.56 |
| 2025-01-02 | Renninger Robert | Sell | 2.9K | $0.56 |
| 2024-12-31 | Worthington Mark | Option exercise | 37K | — |
| 2024-12-31 | Renninger Robert | Option exercise | 12K | — |
| 2024-12-31 | Litton Mark James | Option exercise | 108K | — |
| 2024-12-31 | San Martin Javier | Option exercise | 47K | — |
| 2024-12-31 | CHURCH KEVIN | Option exercise | 37K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06432647 ↗ | A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105 Healthy Volunteers | PHASE1 | Completed | 2024-11-25 |
| NCT05511558 ↗ | A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017) Healthy Volunteers | PHASE1 | Completed | 2022-10-18 |
| NCT05169671 ↗ | Safety, Tolerability, and Pharmacokinetics Study of ATH-1020 Healthy Volunteers | PHASE1 | Completed | 2022-09-09 |
| NCT03298672 ↗ | Safety, Tolerability, and Pharmacokinetics Study of NDX-1017 Alzheimer Disease | PHASE1 | Completed | 2019-09-05 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-23 | Shareholder vote | filing ↗ |
| 2026-05-07 | ResultsReg FDExhibits | filing ↗ |
| 2026-03-31 | Acquisition/dispositionExhibits | filing ↗ |
| 2026-03-26 | ResultsReg FDExhibits | filing ↗ |
| 2026-03-19 | Exec/director changeShareholder voteOtherExhibits | filing ↗ |
| 2026-01-09 | Exec/director change5.03Reg FDOtherExhibits | filing ↗ |
| 2025-12-18 | Material agreement3.02Reg FDOtherExhibits | filing ↗ |
| 2025-12-18 | Material agreement3.02Reg FDOtherExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-23 | 2026-06-22 | 0001193125-26-279425 ↗ |
| 8-K | 2026-05-07 | 2026-05-07 | 0001193125-26-211867 ↗ |
| 10-Q | 2026-05-07 | 2026-03-31 | 0001193125-26-211898 ↗ |
| 10-K | 2026-03-31 | 2025-12-31 | 0001193125-26-134565 ↗ |
| 8-K/A | 2026-03-31 | 2025-12-18 | 0001193125-26-134097 ↗ |
| 8-K | 2026-03-26 | 2026-03-26 | 0001193125-26-126579 ↗ |
| 8-K | 2026-03-19 | 2026-03-18 | 0001193125-26-116123 ↗ |
| 8-K | 2026-01-09 | 2026-01-07 | 0001193125-26-008904 ↗ |
| 8-K | 2025-12-18 | 2025-12-18 | 0001193125-25-323692 ↗ |
| 8-K/A | 2025-12-18 | 2025-12-18 | 0001193125-25-323786 ↗ |
| 8-K | 2025-11-06 | 2025-11-06 | 0001193125-25-269506 ↗ |
| 10-Q | 2025-11-06 | 2025-09-30 | 0001193125-25-269544 ↗ |